FDA Approves Moderna Updated COVID-19 Vaccines
Analysis based on 7 articles · First reported Aug 27, 2026 · Last updated Aug 27, 2026
On August 27, 2026, the U.S. United States — Food and Drug Administration (FDA) approved supplemental Biologics License Applications for Moderna's updated 2026-2027 COVID-19 vaccines, Spikevax and mNEXSPIKE. These vaccines target the JN.1-lineage XFG subvariant of SARS-CoV-2. Spikevax is approved for individuals 6 months and older at high risk or aged 65+, while mNEXSPIKE is approved for those 12 and older at high risk or aged 65+. The approvals follow FDA guidance recommending a monovalent JN.1 lineage XFG composition. Moderna expects the vaccines to be available in the coming days. The Spikevax formula has also received approval from regulators in Europe, South Korea, Singapore, Switzerland, the United Kingdom, and other countries, while mNEXSPIKE has been approved in Japan. Additional regulatory applications are under review globally. Moderna CEO Stéphane Bancel emphasized the ongoing public health threat of COVID-19, citing 2.3 million outpatient visits and 250,000 hospitalizations in the U.S. last year.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard